Home > Boards > US Listed > Biotechs > BrainStorm Cell Therapeutics Inc. (BCLI)

The Registrant is filing this Amendment No. 1

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
condoe3 Member Profile
 
Followed By 1
Posts 630
Boards Moderated 0
Alias Born 02/02/12
160x600 placeholder
Third Clinical Site Initiated for BrainStorm Cell Therapeutic’s Phase 2 Progressive MS Study GlobeNewswire Inc. - 7/2/2019 8:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2019 5:03:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/11/2019 5:03:07 PM
BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting GlobeNewswire Inc. - 5/31/2019 1:00:00 AM
BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study GlobeNewswire Inc. - 5/30/2019 1:00:00 AM
BrainStorm Senior Management to Present at BIO 2019 GlobeNewswire Inc. - 5/28/2019 1:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/13/2019 8:01:41 AM
BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London GlobeNewswire Inc. - 5/13/2019 1:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 5:03:29 PM
BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update GlobeNewswire Inc. - 5/10/2019 5:00:00 PM
BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases GlobeNewswire Inc. - 4/30/2019 4:00:00 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/1/2019 3:35:52 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/29/2019 5:08:02 PM
Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting GlobeNewswire Inc. - 3/28/2019 4:30:00 AM
BrainStorm Announces Grant of an additional New European Patent for NurOwn® GlobeNewswire Inc. - 3/26/2019 6:30:00 AM
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS GlobeNewswire Inc. - 3/14/2019 1:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/12/2019 6:13:38 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/8/2019 5:05:02 PM
BrainStorm to Host Business Update Conference Call GlobeNewswire Inc. - 3/7/2019 4:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/22/2019 5:03:13 PM
BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study GlobeNewswire Inc. - 2/22/2019 7:30:00 AM
BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland GlobeNewswire Inc. - 2/21/2019 6:00:00 AM
BrainStorm Issues a Statement to Patients and Shareholders GlobeNewswire Inc. - 2/19/2019 8:06:49 AM
BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposiu... GlobeNewswire Inc. - 2/4/2019 8:22:51 AM
BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida GlobeNewswire Inc. - 1/25/2019 7:15:00 AM
condoe3   Monday, 04/01/19 04:41:59 PM
Re: Chief-money post# 2498
Post # of 2534 


The Registrant is filing this Amendment No. 1 to Form 10-K for the fiscal year ended December 31, 2018 (“Amendment No. 1”) to correct an error on the cover page of the original Form 10-K as filed with the Securities and Exchange Commission on March 29, 2019 (the “Original Form 10-K”). The cover page of the Original Form 10-K incorrectly showed the total number of shares outstanding. The correct number of shares of the Registrant’s Common Stock outstanding as of March 28, 2019, was 21,490,610, as indicated on the cover page of this Amendment No. 1 (rather than 29,490,610 shares as originally shown, as the result of a typographical error).



No changes are hereby made to the Registrant’s financial statements. Other than the change discussed above and the filing of the currently dated Section 302 certifications and updated XBRL data under Item 15 of Part IV of this Amendment No. 1, no changes have been made to the Original Form 10-K or the exhibits filed therewith. As such, this Amendment No. 1 should be read in conjunction with the Original Form 10-K.



The information contained in this Amendment No. 1 does not reflect events occurring subsequent to the filing of the Original Form 10-K.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist